(MedPage Today) — Some participants in a weight-loss trial of retatrutide, an investigational triple-hormone receptor agonist, dropped out because they thought they were losing too much weight. (New York Times)
Meanwhile, UBT251, another investigational…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/120024
Author :
Publish date : 2026-02-24 19:55:00
Copyright for syndicated content belongs to the linked Source.
